<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000507586"><TermName>Mylosar</TermName><TermPronunciation>(MY-loh-sar)</TermPronunciation><TermDefinition><DefinitionText>A drug that is used to treat myelodysplastic syndromes and is being studied in the treatment of other types of cancer. It belongs to the family of drugs called antimetabolites. Also called azacitidine and Vidaza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000718677" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Mylosar&quot;" language="en" id="_3"/><MediaLink ref="CDR0000718676" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Mylosar&quot;" language="es" id="_4"/><SpanishTermName>Mylosar</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa en el tratamiento de los síndromes mielodisplásicos y que está en estudio para el tratamiento de otros tipos de cáncer. Es un tipo de antimetabolito. También se llama azacitidina y Vidaza.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2006-09-15</DateFirstPublished><DateLastModified>2007-03-15</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000496239">Azacitidine</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
